dc.contributor.author | Çakır, Akın | |
dc.contributor.author | Erden, Burak | |
dc.contributor.author | Aydın, Ali | |
dc.contributor.author | Bölükbaşı, Selim | |
dc.contributor.author | Aydın, Ali | |
dc.contributor.author | Yurttasever Ocak, Serap | |
dc.contributor.author | Maden, Gamze | |
dc.contributor.author | Elçioğlu, Mustafa Nuri | |
dc.date.accessioned | 2019-12-27T13:55:23Z | |
dc.date.available | 2019-12-27T13:55:23Z | |
dc.date.issued | 2019 | en_US |
dc.identifier.citation | Çakır, A., Erden, B., Bölükbaşı, S., Aydın, A., Yurttasever Ocak, S., Maden, G. ... Elçioğlu, M. N. (2019). Comparison of the effect of ranibizumab and dexamethasone implant in diabetic macular edema with concurrent epiretinal membrane. Journal Francais D Ophtalmologie, 42(7), 683-689. https://doi.org/10.1016/j.jfo.2019.02.007 | en_US |
dc.identifier.issn | 0181-5512 | |
dc.identifier.issn | 1773-0597 | |
dc.identifier.uri | https://doi.org/10.1016/j.jfo.2019.02.007 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/4779 | |
dc.description.abstract | Objective. - To compare the efficacy and safety of intravitreal ranibizumab (RZB) injections and intravitreal dexamethasone (DEX) implant in diabetic macular edema (DME) with concurrent epiretinal membrane (ERM). Methods. - This was a retrospective, observational, comparative study. Medical records of DME patients with concurrent ERM were retrospectively reviewed. Seventeen eyes of 16 patients treated with 3 consecutive monthly RZB injections (RZB group) and 22 eyes of 18 patients treated with a DEX implant (DEX group) were included. The groups were compared at baseline, 1st, 2nd, 3rd and 4th months in terms of best-corrected visual acuity (BCVA), central macular thickness (CMT), and intraocular pressure (IOP). Results. - Eighteen of the 39 eyes (46.1%) were phakic at baseline, 9 (52.9%) of which were treated with RZB, whereas 9 (40.9%) were treated with DEX implant (P = 0.528). Although CMT improved significantly in both the RZB and DEX groups (P<0.001); the trend was different (P=0.003). The mean change in CMT at 1 month in the DEX group was greater (DEX: 188.2 +/- 142.7 mu m; RZB: 95.7 +/- 110.7 mu m; P=0.034); it was in favor of RZB group at the 3rd and 4th months (DEX: -52.7 +/- 86.9 mu m; RZB: 1.4 +/- 31.4 mu m; P=0.012. DEX: -63 +/- 67.3 mu m; RZB: -5.8 +/- 43.9 mu m; P=0.004, respectively). BCVA improved significantly in both groups (P < 0.001). There was no statistical difference between the groups with regard to gain in BCVA or IOP change throughout the study period (P=0.572, P=0.064, respectively). Conclusion. - Both RZB and DEX are effective in improving anatomical and visual outcomes in DME with concurrent ERM. The DEX group was associated with a prompt anatomic response, but with a gradual decrease from 3rd month. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Masson Editeur | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Ranibizumab | en_US |
dc.subject | Dexamethasone | en_US |
dc.subject | Epiretinal Membrane | en_US |
dc.subject | Diabetic Macular Edema | en_US |
dc.title | Comparison of the effect of ranibizumab and dexamethasone implant in diabetic macular edema with concurrent epiretinal membrane | en_US |
dc.type | article | en_US |
dc.relation.ispartof | Journal Francais D Ophtalmologie | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Göz Hastalıkları Ana Bilim Dalı | en_US |
dc.authorid | 0000-0002-0972-3833 | en_US |
dc.identifier.volume | 42 | en_US |
dc.identifier.issue | 7 | en_US |
dc.identifier.startpage | 683 | en_US |
dc.identifier.endpage | 689 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.doi | 10.1016/j.jfo.2019.02.007 | en_US |
dc.identifier.wosquality | Q4 | en_US |
dc.identifier.scopusquality | Q3 | en_US |